查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球膀胱过度活动症治疗市场
市场调查报告书
商品编码
1169022

2022-2029 年全球膀胱过度活动症治疗市场

Global Overactive Bladder Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期内（2022 年至 2029 年），膀胱过度活动症治疗的全球市场规模预计将以 3.6% 的复合年增长率增长。

膀胱过度活动症是一组以膀胱壁突然、不自主的肌肉收缩为特征的排尿综合征。 结果，即使膀胱中只有少量尿液，排尿的衝动也会立即出现并且难以控制。 其他症状包括夜尿和尿失禁。

市场动态

推动全球膀胱过度活动症治疗市场的主要因素包括膀胱过度活动症患病率上升、老年人口增加、神经系统疾病和肥胖症增加、主要市场参与者加大研发力度等。

研发投资的增加和技术进步的不断增加预计将推动市场的增长。

由于技术进步不断增加、人口老龄化加剧、研发投资激增、膀胱过度活动症患者数量增加以及新兴国家在医疗基础设施中使用最新技术改进新产品，膀胱过度活动症治疗市场正在增长。拖走。

此外，主要的主要市场参与者和製造商不断投资于新的研发，并增加投资以开发新药和治疗方法，例如具有创新作用机制的神经肌肉阻滞剂。它正在发挥作用。 增加投资和研发将推动市场的增长。 此外，预计主要参与者提供的技术先进的产品也将在市场增长中发挥重要作用。

与这些膀胱过度活动症治疗相关的各种新产品发布、研究和提高认识的活动正在促进市场的增长。 例如，2021 年 2 月，艾伯维旗下公司艾尔建（Allergan）宣布其用于不能耐受抗胆碱能药物的 5 岁及以上患者的直立性过度活动（膀胱肌）相关神经系统症状的 BOTOX 宣布获批。

与膀胱过度活动症治疗相关的副作用预计会阻碍市场增长。

使用抗毒蕈碱药后会出现一些副作用，例如便秘、口干、视力模糊、尿路感染、眼睛发痒或干涩、嗜睡和尿潴留。 偶尔，人们会出现危及生命的心律失常，但机率非常小。 由于口干而喝水会加剧膀胱过度活动症的症状。

认知度不足也是製约市场增长的一大因素。 在低收入国家，人们没有意识到膀胱过度活动症的流行，缺乏报销方案阻碍了市场增长。

COVID-19 影响分析

疫情对全球金融预期、运营和危机应对策略产生了积极影响。 COVID-19 的爆发严重影响了医疗保健行业。 由于 COVID，膀胱过度活动症治疗市场取得了巨大收益。 在 COVID 患者中也观察到与膀胱相关的问题，例如膀胱过度活动症。 COVID 影响了患者的膀胱。 主要製造商已经启动了各种研究和临床试验。 世界各地正在开展各种举措、产品发布、合作和合併，推动市场增长。 例如，2022 年 7 月，Urovant Sciences 宣布与 Pierre Fabre Medicament 达成许可协议，在欧洲地区将用于治疗膀胱过度活动症的 Vibegron 商业化。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第4章市场动态

  • 市场影响因素
    • 司机
      • 增加研发投资
      • 不断进步的技术进步
    • 约束因素
      • 与膀胱过度活动症治疗相关的副作用
    • 商机
    • 影响分析

第5章行业分析

  • 波特的五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型分类

  • 神经刺激疗法
    • □神经刺激
    • 经皮胫神经刺激疗法
  • 行为干预
    • 骨盆底肌肉锻炼
    • 健康体重
    • 生物反馈
    • 膀胱训练
    • 其他
  • 药物治疗
    • 具有抗胆碱能作用的药物
      • 奥昔布宁（地托泮）
      • 托特罗定（Detrol）
      • Torspium (Sanctura XR)
      • 非索罗定（託拜厄斯）
      • 索利那新 (Vesicare)
      • 达非那新 (Inaverex)
    • β3 肾上腺素激动剂
      • 米拉贝隆 (milbetriq)
      • Vivegron（Gemtesa）
  • 膀胱肉毒毒素注射
  • 手术
    • 人工括约肌手术
    • 膀胱增大术
    • 括约肌切除术

第 8 章按疾病类型分类

  • 特发性膀胱过度活动症
  • 神经源性膀胱过度活动症

第9章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第10章竞争格局

  • 主要发展和战略
  • 公司股票分析
  • 产品基准
  • 值得关注的主要公司名单

第11章公司简介

  • 美敦力
    • 公司概况
    • 产品组合和说明
    • 主要亮点
    • 财务摘要
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Astellas Pharma Inc.
  • Teva Pharmaceutical Industries Limited
  • AbbVie Inc.
  • Accord Healthcare Inc.
  • Laborie
  • Macleods Pharmaceuticals Ltd
  • Urovant Sciences

第12章 全球膀胱过度活动症治疗市场-DataM

简介目录
Product Code: DMPH1214

Market Overview

The global overactive bladder treatment market size was valued at US$ XX million in 2022 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 3.6% during the forecast period (2022-2029).

An overactive bladder is a group of urinary syndromes characterized by sudden, involuntary muscle contraction in the wall of the urinary bladder. This results in an immediate, compelling need to urinate that is difficult to suppress, even though the bladder may only contain a small amount of urine. Other symptoms include nocturia or urinary incontinence.

Market Dynamics

The major factors driving the global overactive bladder treatment market are the rise in the prevalence of overactive bladder, growth in the geriatric population, an increase in neurological disorders and obesity, and an increase in R&D by major market players.

The increasing research and development investments and rising technological advancements are expected to drive the market's growth.

The overactive bladder treatment market is driven by rising advancements in technology, an increase in the geriatric population, a surge in research and development investments, an increasing number of overactive bladder patients and improvements in novel products using the latest technology in medical infrastructure in emerging markets.

Furthermore, prominent key market players and manufacturers are continuously working on new research and development and increasing investments to develop new drugs and therapies, such as neuromuscular blocking agents with innovative mechanisms of action. A rise in investment and R&D boost market growth. Moreover, the availability of technologically advanced products by key players is also expected to play a vital role in the market's growth.

Various novel product launches, research studies, and rising awareness initiatives about these Overactive Bladder Treatments contribute to the market's growth. For instance, in February 2021, Allergan, a company of AbbVie, announced the approval of its BOTOX for detrusor overactivity (bladder muscle) related to the neurologic condition in patients aged five years or older who have intolerability to anticholinergic medicines.

Side effects associated with overactive bladder treatments are expected to hamper the market's growth.

Several side effects are observed after using antimuscarinic medicines, such as constipation, dry mouth, blurred vision, urinary tract infection, itchy or dry eyes, drowsiness and urinary retention. Sometimes people experience irregular heart rhythms that can be life-threatening, but their chances are very rare. Drinking water due to dry mouth can aggravate the overactive bladder symptoms.

Lack of awareness is also a leading factor restraining the market's growth. In low-income countries, people are unaware of overactive bladder prevalence, and the unavailability of reimbursement scenarios hinders the market's growth.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The overactive bladder treatment market has experienced huge profits due to COVID. In covid patients, bladder-related problems such as overactive bladder were also observed. COVID affected the bladders of patients. Key manufacturers have started various research and clinical trials. Various initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in July 2022, Urovant Sciences announced its license agreement with Pierre Fabre Medicament for Vibegron commercialization for overactive bladder treatment in European Areas.

Segment Analysis

The nerve stimulation segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The nerve stimulation treatment segment is the highest market holder in the global overactive bladder treatment market. The global overactive bladder treatment market is segmented based on treatment type as nerve stimulation, behavioral intervention, medications, botulinum toxin injections and surgery. The nerve stimulation segment is the largest market shareholder due to its inherent advantages over other treatments, increasing technological advancements and novel product launches.

Neuromodulation or nerve stimulation is an effective way to treat an overactive bladder. An electrode is implanted under the skin to stimulate nerves with electricity around the bladder. The electric signals traveling from the bladder to the brain are blocked with electricity reducing the symptoms of an overactive bladder are blocked. These therapies are of two types: sacral neuromodulation and percutaneous tibial nerve stimulation.

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in April 2021, Medtronic, the medical technology company, announced receiving approval from the United States Food and Drug Administration to continue the investigational device exemption trial for evaluating its implantable tibial neuromodulation device, an internally developed therapy specially developed for bladder incontinence symptom's relief.

Geographical Analysis

North America holds the largest market share in the global overactive bladder treatment market.

North America dominates the global overactive bladder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US and the growing geriatric population. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of overactive bladder medications and neurostimulation therapies, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region contribute to the overactive bladder treatment market growth.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in Jan 2021, Astellas Phrma Inc. announced its priority review acceptance by the United States Food and Drugs Administration for Mirabegron or Myrbetriq tablets, its novel drug application for neurogenic detrusor overactivity treatment in pediatric patients.

Competitive Landscape

The overactive bladder treatment market is highly competitive with local and global companies' presence. Medtronic, Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., Teva Pharmaceutical Industries Limited, AbbVie Inc., Accord Healthcare Inc., Laborie, Macleods Pharmaceuticals Ltd, Urovant Sciences and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in November 2022, Urovant Sciences, Sumitovant Biopharma Ltd's subsidiary, announced its partnership with Thinx Inc, an incontinence and period underwear brand. They launched "Time To Go," an educational campaign to educate people about overactive bladders, such as their symptoms and how to manage them.

Medtronic

Overview: Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.

Product Portfolio:

Medtronic Bladder Control Therapy: This is a therapy in which the InterStim system delivers sacral neuromodulation. It utilizes an implantable device to deliver electrical pulses to sacral nerves near the tailbone hence creating miscommunication between sacral nerves and the brain to control the symptoms.

Key Development: In February 2022, Medtronic plc, a healthcare technology company, announced that its InterStim X got approved by the United States Food and Drug Administration. This new generation of InterStim recharge-free device is an advanced therapy system to provide sacral neuromodulation therapy for bowel and bladder incontinence,

The global overactive bladder treatment market report would provide access to approx.: 45+market data table, 40+figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing research and development investment
      • 4.1.1.2. Rising technological advancements
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with overactive bladder treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis
  • 5.4 Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Nerve Stimulation *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
    • 7.2.3. Sacral Nerve Stimulation
    • 7.2.4. Percutaneous Tibial Nerve Stimulation
  • 7.3. Behavioural Intervention
    • 7.3.1. Pelvic Floor Muscle Exercise
    • 7.3.2. Healthy weight
    • 7.3.3. Biofeedback
    • 7.3.4. Bladder Training
    • 7.3.5. Others
  • 7.4. Medication
    • 7.4.1. Anticholinergic medications
      • 7.4.1.1. Oxybutynin (Ditropan)
      • 7.4.1.2. Tolterodine (Detrol)
      • 7.4.1.3. Trospium (Sanctura XR)
      • 7.4.1.4. Fesoterodine (Toviaz)
      • 7.4.1.5. Solifenacin (Vesicare)
      • 7.4.1.6. Darifenacin (Enablex)
    • 7.4.2. Beta-3 adrenergic medication
      • 7.4.2.1. Mirabegron (Myrbetriq)
      • 7.4.2.2. Vibegron (Gemtesa)
  • 7.5. Bladder Botulinum Toxin Injections
  • 7.6. Surgery
    • 7.6.1. Artificial Sphincter Surgery
    • 7.6.2. Bladder Augmentation
    • 7.6.3. Sphincter Resection

8. By Disease Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 8.1.2. Market Attractiveness Index, By Disease Type
  • 8.2. Idiopathic Overactive Bladder*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Neurogenic Overactive Bladder

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Products Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Medtronic *
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Pfizer Inc.
  • 11.3. Johnson & Johnson Services, Inc.
  • 11.4. Astellas Pharma Inc.
  • 11.5. Teva Pharmaceutical Industries Limited
  • 11.6. AbbVie Inc.
  • 11.7. Accord Healthcare Inc.
  • 11.8. Laborie
  • 11.9. Macleods Pharmaceuticals Ltd
  • 11.10. Urovant Sciences

LIST NOT EXHAUSTIVE

12. Global Overactive Bladder Treatment Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Application
  • 12.3. Contact Us